NCT04838704View on ClinicalTrials.gov

Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation

NACompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Graft Versus Host Disease
Interventions
DRUG

Ruxolitinib+Calcineurin inhibitor+Methotrexate

low-dose ruxolitinib combine with calcineurin inhibitor and short course of methotrexate.

DRUG

Calcineurin Inhibitor+Methotrexate+Mycophenolate mofetil

calcineurin inhibitor and short course of methotrexate and mycophenolate mofetil

Trial Locations (1)

310006

The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

The Children's Hospital of Zhejiang University School of Medicine

OTHER

collaborator

Yinzhou Hospital Affiliated to Medical School of Ningbo University

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Zhejiang University

OTHER

NCT04838704 - Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter